The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, discusses outcomes for patients with multiple myeloma (MM) who received lenalidomide as first-line maintenance therapy following autologous stem cell transplantation (autoSCT), as evaluated from the PREAMBLE registry. The analysis revealed the median progression-free survival (PFS) in this patient population was 2.5 years, highlighting the need for more effective maintenance treatment strategies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Takeda, Janssen, Pfizer, Karyopharm, Harpoon, Legend, Sanofi, Bristol Myers Squibb
Research Funding: Takeda, Sanofi, Bristol Myers Squibb
